Evaluation of Spinal Cord Stimulation Pulse Rate On Clinical Outcomes

NCT ID: NCT02549183

Last Updated: 2020-12-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

22 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-06-01

Study Completion Date

2017-07-13

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Clinical study to estimate the optimal frequency for stimulation of the spinal cord to achieve relief from back pain.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a feasibility study to identify the optimal frequency for stimulation of the spinal cord to achieve maximum reduction in neuropathic back pain as measured by average Numerical rating Scale.

Twenty patients who suffer from back more than leg pain will be recruited into the study once they have satisfactory pain relief from both low and high frequency stimulations. Each patient will then receive stimulation at four different frequencies for 2-3 weeks in a random and blinded order. Their pain scores and function will be assessed using a variety of different tools. The data will then be used to estimate the optimal frequency.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Back Pain Neuralgia

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Spinal Cord Stimulation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm 1

Boston Scientific PRECISION Spinal Cord Stimulator System with MultiWave Technology programmed to A KHz

Group Type ACTIVE_COMPARATOR

Boston Scientific PRECISION Spinal Cord Stimulator System

Intervention Type DEVICE

Spinal cord stimulation randomly programmed to KHz frequencies; A, B, C and D Kilo Hertz.

Arm 2

Boston Scientific PRECISION Spinal Cord Stimulator System with MultiWave Technology programmed to B KHz

Group Type ACTIVE_COMPARATOR

Boston Scientific PRECISION Spinal Cord Stimulator System

Intervention Type DEVICE

Spinal cord stimulation randomly programmed to KHz frequencies; A, B, C and D Kilo Hertz.

Arm 3

Boston Scientific PRECISION Spinal Cord Stimulator System with MultiWave Technology programmed to C KHz

Group Type ACTIVE_COMPARATOR

Boston Scientific PRECISION Spinal Cord Stimulator System

Intervention Type DEVICE

Spinal cord stimulation randomly programmed to KHz frequencies; A, B, C and D Kilo Hertz.

Arm 4

Boston Scientific PRECISION Spinal Cord Stimulator System with MultiWave Technology programmed to D KHz

Group Type ACTIVE_COMPARATOR

Boston Scientific PRECISION Spinal Cord Stimulator System

Intervention Type DEVICE

Spinal cord stimulation randomly programmed to KHz frequencies; A, B, C and D Kilo Hertz.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Boston Scientific PRECISION Spinal Cord Stimulator System

Spinal cord stimulation randomly programmed to KHz frequencies; A, B, C and D Kilo Hertz.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Complaint of persistent or recurrent low back pain, with or without equal or lesser leg pain, for at least 90 days prior to Screen.
2. Received at least 90 days of documented pain management care to address the primary pain complaint, prior to Screening (e.g. medication, physical therapy.)
3. No back surgery within 6 months prior to Screening.
4. Average low back pain intensity, during the position/activity, which routinely causes worst pain, of 5 or greater on a 0-10 numerical rating scale during Baseline period based on eDiary.
5. If taking prescription opioids for primary chronic pain complaint (low back and/or leg pain), must have been on a stable prescription (same drug(s) and dose(s)) 30 days prior to Screening to a total of less than 180 mg Oral Morphine equivalent
6. Willing and able to comply with all protocol-required procedures and assessments/evaluations (e.g. willing to comply with opioid prescription lock from the Baseline visit through End of Rate Randomization and protocol required stimulation parameter locks, complete daily eDiary).
7. 18 years of age or older when written informed consent is obtained.
8. If female of childbearing potential: not pregnant, as evidenced by a negative pregnancy test at Screening.
9. Subject signed a valid, IRB-approved informed consent form (ICF) provided in English.
10. Baseline Oswestry Disability Index score ≥ 20 and ≤ 80.
11. Received at least 30 per cent reduction in NRS of average low back pain intensity from Baseline during the end of Post Implant HF10 Sweet-Spot Search as recorded in the eDiary.

Exclusion Criteria

1. Average worst leg pain intensity is greater than average worst low back pain intensity as reported during Baseline period based on eDiary.
2. Radiographic evidence of spinal instability requiring fusion.
3. Primary pain complaint of vascular origin (e.g. peripheral vascular disease).
4. Spinal pain secondary to neoplasm, infection, autoimmune disorder with spinal involvement, or a spinal metabolic disorder.
5. Any pain-related diagnosis or medical/psychological condition that, in the clinician's best judgment might confound reporting of study outcomes (e.g. pelvic pain, angina pain, chronic migraine.
6. Participating (or intends to participate) in another clinical study.
7. Terminal illness with anticipated survival 1 year.
8. Current condition associated with risk of immunocompromised that might increase risk of infection during study duration.
9. Currently on any anticoagulant medications that cannot be discontinued during perioperative period.
10. Are pregnant/lactating or not using adequate birth control.
11. Have untreated major psychiatric comorbidity, serious drug related behaviour issues.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

North Bristol NHS Trust

OTHER

Sponsor Role collaborator

Mid and South Essex NHS Foundation Trust

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Simon Thomson, MD

Role: STUDY_CHAIR

National Health Service, United Kingdom

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

North Bristol NHS Trust

Bristol, Avon, United Kingdom

Site Status

Orsett Hospital

Orsett, Essex, United Kingdom

Site Status

South Tees NHS Foundation Trust

Middlesbrough, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Thomson SJ, Tavakkolizadeh M, Love-Jones S, Patel NK, Gu JW, Bains A, Doan Q, Moffitt M. Effects of Rate on Analgesia in Kilohertz Frequency Spinal Cord Stimulation: Results of the PROCO Randomized Controlled Trial. Neuromodulation. 2018 Jan;21(1):67-76. doi: 10.1111/ner.12746. Epub 2017 Dec 8.

Reference Type RESULT
PMID: 29220121 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

B726

Identifier Type: -

Identifier Source: org_study_id